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ABSTRACT 
Background: Interferon-α (IFNα) was the first effective drug therapy for hairy cell leukemia (HCL). Nowadays, 
it is used as an alternative treatment in selected patients. Due to unlimited treatment time, monitoring and early 
prediction of response are important. Moreover, IFNα is used in the therapy of chronic hepatitis C, where a 
single nucleotide polymorphism of Interleukin-28B gene (IL28B) correlates with therapy response. The role of 
this polymorphism in therapy response of IFNα-treated patients with HCL is unknown.  
Methods: 37 HCL patients treated between 1978 and 2014 were included in this study. Treatment strategy and 
response parameters (blood cell counts, soluble Interleukin-2 receptor (sIL2R) and bone marrow examination) 
have been assessed. Relative decrease of sIL2R was correlated with outcome parameters. Response parameters 
of IFNα-treated patients were correlated with IL28B polymorphism.  
Results: 21 patients were analyzed for the correlation of sIL2R ratio and outcome. After 1 and 3 months of 
therapy (IFNα or Cladribine (CDA)), the median sIL2R level showed a relative decrease of 79% and 91%. These 
decreases significantly correlate with time to complete remission (CR, p=0.029 and p=0.018). Correlation 
analyses of IL28B genotype with outcome parameters are not significant. Six patients (16%) were diagnosed 
with secondary malignancies and one death was registered (median follow-up time: 14 years).  
Conclusions: IFNα is a safe, effective and well-tolerated long-term treatment in HCL. Relative decreases of 
sIL2R levels correlate with time to CR and are useful as early predictor for response. There is no significant 
correlation between IL28B polymorphism and treatment response to IFNα. 
Keywords 
Hairy cell leukemia, IL28B polymorphism, Interferon-alpha, soluble Interleukin-2 Receptor, Cladribine  
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INTRODUCTION 
Hairy cell leukemia is a hematopoietic neoplasm of mature B-lymphocytes [1]. The first comprehensive 
publication on HCL was published in 1958 by Bouroncle et al. calling the disease "leukemic 
reticuloendotheliosis" [2]. An incidence rate of 0.3 HCL cases per 100'000 persons is estimated [3]. Male 
patients are 3 to 4 times more often affected than female. The median age at diagnosis varies from 55 to 65 years 
[3, 4]. Symptoms are not specific, but mainly related to cytopenia and splenomegaly. Fatigue, infection, 
hemorrhagic diathesis as well as abdominal discomfort are seen in up to 51% of cases [5]. Based on the typical 
morphology, the phosphatase with tartrate stain and characteristic flow cytometry showing expression of CD11c, 
CD25 and CD 103 [6], the diagnosis can be made with high accuracy. Nowadays, the BRAF V600E mutation is 
an additional helpful diagnostic test with high specificity [7]. The course of illness is mainly indolent. With the 
introduction of drug therapies (IFNα 1984, purine nucleoside analogues (PNA) 1990, Rituximab 1999) a 
significant increase in survival was observed. The most impressive improvement of survival is described after 
1984 with the introduction of IFNα as the first specific therapy for HCL [8]. IFNα induces a rapid normalization 
of the peripheral blood counts resulting in a significant lower rate of infections than PNA [9]. In addition, long-
term therapy with IFNα is often well-tolerated with durable disease control even on very low doses of treatment 
(Benz et al., 2009). However, once IFNα is completely stopped, disease recurrence is observed invariably.  
Nowadays, the recommended first line treatment are the two purine nucleoside analogues (PNA) Cladribine and 
Pentostatin, because of their high rates of CR (76-95%) and limited treatment time. Nonetheless, IFNα is still an 
important alternative therapy for selected patients. Beside patients who failed PNA therapy, it can be used as 
treatment induction in those with high risk for infections due to very low granulocytes [10, 11]. Novel treatment 
options as BRAF inhibitor vemurafenib and moxetumomab pasudotox, an anti-CD22 recombinant immunotoxin 
show promising results in early trial phase. However, they are not established in the standard treatment [12, 13]. 
Until recently, IFNα together with Ribavirin were recommended as first line therapy for hepatitis C virus 
infection. This combination induces a sustained viral response (SVR) in one half of the patients of European 
ancestry [14, 15]. One explanation for this significant difference was found by Ge et. al in a genome-wide 
association study of more than 1'600 individuals. They found a single nucleotide polymorphism (SNP) of the 
IL28B gene (chromosome 19, rs12979860), which was associated with a significantly greater rate of SVR as 
well as a twofold higher treatment response for genotype "CC" [16]. McCarthy et al. validated these findings in 
1'021 hepatitis C patients and concluded that the SNP-marker rs12979860 is a significant predictor for treatment 
response to IFNα in patients with chronic hepatitis C.  
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In this study, we analyzed our HCL cohort with a special focus on the IFNα treated patients in regards to the 
impact of IL28B polymorphism and response to IFNα. Due to the important role of long-term follow-up in HCL 
patients, a newly elaborated sIL2 ratio was correlated to established outcome parameters.  
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METHODS 
The diagnosis of all HCL patients was based on clinical presentation, peripheral blood counts and examination 
of bone marrow as well as flow cytometry and imaging of the spleen (ultrasound or computer tomography). 
From 2012 on, BRAF V600E mutation was as well taken into account. HCL patients at the University hospital of 
Zurich and the Kantonsspital Münsterlingen in Switzerland were consecutively informed about the possibility of 
participating in this retrospective study. Demographics and treatment specific data were collected from the 
electronic patient files of the two hospitals. To monitor treatment response, sIL2R was regularly measured 
(Cellfree® Human sIL-2R ELISA – Kit. Thermo Scientific) since the correlation between the amount of HCL 
cells and sIL2R value is well-established [17, 18]. In addition, sIL2R has been shown to be very useful in IFNα 
treated patients [19]. However, absolute sIL2R values of different patient are not comparable. We therefore 
established a ratio of the initial and follow-up value. To validate the usefulness of this ratio, we correlated the 
value to established prognostic parameters like CR. 
EDTA blood samples were collected for IL28B genotyping. Samples were anonymized. Genomic DNA was 
isolated using the MagNaPure Compact instrument (Roche Diagnostics) at the laboratory of the Institute for 
Clinical Chemistry of the University Hospital Zurich. The IL28B single nucleotide polymorphism (rs 12979860) 
was determined by PCR followed by melting curve analysis (LightMix Kit IL-28B, Tib Molbio, Germany) on a 
LightCycler 2.0 instrument.  
The correlation of genotypes and therapy response was studied with a special focus on the patients treated with 
IFNα. The following response criteria were used: Complete remission was defined as hemoglobin concentration 
of more than 120 g/l, absolute granulocyte count more than 1.5 G/l, platelet count of more than 100 G/l and 
absence of hairy cells in the peripheral blood or, if provided, bone marrow biopsy [4]. A primary resistance was 
diagnosed, if no normalization of peripheral blood counts was achieved after 3 months of therapy. Progressive 
cytopenia with proven hairy cells after CR was counted as relapse. These were, in general, verified by 
examination of bone marrow.  
Statistical analyses were made with IBM® SPSS® version 21.0. Continuous data were tested for normality and 
presented as median and interquartile range (IQR). Non-parametric (Mann-Whitney) and parametric tests (t-test) 
were applied for group comparisons (e.g. CC genotype vs. non-CC genotype) as appropriate. Correlations of 
sIL2R ratio were evaluated using spearman's correlation coefficient rho. Linear regression was used to test the 
association between outcome parameters and genotypes. A two-sided p<0.05 was considered significant. 
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The local ethics committee approved this study (KEK ZH NR 2010-0237) and each participant signed a written 
informed consent and all procedures followed were in accordance with the Helsinki Declaration of 1975, as 
revised in 2008 [20]. 
PATIENTS CHARACTERISTICS 
Thirty-seven patients could be included and analyzed. Patients were diagnosed for HCL between 1978 and end-
2014. The vast majority of patients (26) were treated with IFNα, 24 of whom had first-line and 2 second-line 
therapy. The baseline characteristics are shown in table 1. The median follow-up time was 14 years (IQR 7-23y). 
Median age at diagnosis was 45 years (IQR 40-52y). Males were predominant (29; 78%, sex-rate ratio 3.6:1). At 
diagnosis, 10 patients (30%) presented with infections, in 11 patients (33%) fatigue was the main symptom and 
in 8 patients (24%) the diagnosis was made during a routine check. Only 4 patients (12%) complained about 
abdominal pain, even though 29 patients (88%) showed splenomegaly. In the majority, laboratory findings were 
anemia (71%), neutropenia (83%), monocytopenia (85%) and/or thrombocytopenia (88%). Pancytopenia was 
detected in 43%. Hairy cells in peripheral blood examination were found in 90% as well as a normal lactate 
dehydrogenase (LDH; 91%, normal value 240-480 U/l [21]). BRAF V600E mutation has been assessed at 
diagnosis in 4 cases. In all cases, the mutation was present. Additional information on initial hematological 
parameters is provided in table 1. Regarding the distribution of the IL28B polymorphism in the whole cohort, 15 
patients (41%) showed genotype CC and 19 patients (51 %) genotype CT or TT. In 3 cases (8%), genotyping 
was not successful. Finally, 3 patients (12.5%) were lost to follow-up.  
The correlation between IL28B genotype and response to IFNα was analyzed in the patients treated with IFNα as 
first-line therapy. Genotyping was unsuccessful in 2 patients in this subgroup, who were subsequently excluded. 
The remaining cohort of 22 patients was split into 2 groups according to genotype (CC vs. CT/TT). The 
characteristics for these groups are summarized in table 2. The median follow-up time was 17 years (IQR 13-
28). The initial dose was in general 3x3 Mio IU/week and dosing of maintenance therapy was mainly adapted as 
shown earlier [19]. 
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RESULTS I: STUDY COHORT 
Correlation sIL2R ratio with time to complete remission 
For the evaluation of the levels of sIL2R all 37 patients of the study group were included. The required lab data 
were available in 21 cases. All patients showed a significantly increased sIL2R level at diagnosis, with values 
above 4'000 U/ml (table 1). Since absolute values of sIL2R show high inter-individual variability, we built a 
ratio between the pretreatment measurement and the one after 1 month (median 36d, IQR 29-43d) and 3 months 
(median 89d, IQR 83-107d). Relative decreases of the median sIL2R level of 79% (after 1 month) and 91% 
(after 3 months) were found. After 3 months of treatment, 9 patients (43%) showed a sIL2R level <1'000 U/ml. 
Due to the fact that CR rate is related to relapse-free survival [22], we correlated the sIL2R ratio to time to CR. It 
resulted a positive correlation for the time to CR after 1 month (rho=0.515, p=0.029) and 3 months (rho=0.550, 
p=0.018).  
RESULTS II: IFN-SUBGROUP 
Follow-up data 
Follow-up data for the IFN-subgroup of 22 patients is shown in table 3. Complications occurring on IFNα-
therapy were evaluated in accordance with CTCAE v4.0 [23]. Altogether, 15 patients (68%) did suffer from one 
or more complications due to therapy. The most common side effects were infections of grade I and II (7 cases) 
and persistent blood count changes (grade I and II, 5 cases). Except for two cases with grade III complications 
(infections with hospitalization), the remaining events were of grade I or II: intolerable flu-like symptoms (4 
cases) and psychiatric symptoms (in particular lethargy, 3 cases). No grade IV event caused by IFNα was 
registered. In 4 cases, therapy was interrupted due to ≥1 of above-mentioned complications. In 3 patients relapse 
and in 1 patient primary resistance were the reasons for discontinuing IFNα-treatment. Eight patients were 
treated by a second-line therapy. This therapy was in 6 cases CDA, once Rituximab and one patient was 
retreated with IFNα. Eleven patients had a maintenance therapy with very low doses of IFNα, which was in the 
majority (7 patients, 63%)  
3 Mio IU per one or two weeks. 
Genotype and outcome 
In order to examine the impact of genotype on the outcome, 2 different statistical analyses were conducted. At 
first, differences in the outcome of the 2 groups of genotype were explored using  
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Mann-Whitney test. It resulted neither significant differences between the genotypes for time on treatment 
(p=0.872) and time to CR (p=1.000) nor for sIL2R ratio after 1 month (p=0.343) and 3 months (p=0.530).  
Secondly, the association between genotype and outcome was examined using linear regression. Evaluating 
adjusted R2, genotype explained 3.7% of variability of sIL2R ratio after 1 month (R2=0.037) and 0.5% of time to 
CR (R2=0.005). The variability of therapy time (R2=-0.048) and sIL2R ratio after 3 months (R2=-0.094) was not 
explained by genotype. Altogether, adjusted R2 of these analyses complied with no or little effect size. The 
results are not statistical significant.  
RESULTS III: SURVIVAL AND SECONDARY MALIGNANCIES 
During the period of follow-up (median 14y), there was 1 death registered. The cause of death was a septic 
shock in aplasia, which was induced by third line therapy with Rituximab/Bendamustin at the age of 71 years, 31 
years after initial diagnosis of HCL.  
Regarding late effects, 6 patients (16%) suffered from secondary malignancies (table 4). Splenectomy was 
performed in 50% of these patients, mainly in in the early period of our observation time. Three neoplasias 
occurred while on IFNα therapy, 2 patients had IFNα and PNA therapy and one patient had only PNA therapy. 3 
patients developed skin cancer (2 non-melanoma types), whereas the remaining had cancer of the prostate in two 
cases and breast cancer in one case. In average, secondary tumors were diagnosed 8 years after diagnosis of HCL 
(median, IQR 6-16y). 
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DISCUSSION 
This retrospective study presents data of 37 HCL patients with a very long median follow-up time of 14 years. 
The IFNα treated subgroup was even observed for a median time of 17 years.  
The detailed analyses of our patients show interesting findings. Whereas infections as first symptom are well 
known, the correlation between spleen enlargement and absent abdominal symptom is somehow surprising. 
However, this finding can be explained by the rather slightly enlarged spleen size (median 17 cm) and the 
relatively young age at diagnosis. The neutropenia and specifically the missing monocytes are a typical finding 
in HCL patients [5, 24, 25]. As HCL cells proliferate only slowly, LDH value would be estimated to be almost 
always in the normal range. In contrast to Bouafia et al., who found elevated levels in HCL patients [26], we 
found the expected normal LDH levels in the great majority of our patients. Therefore, LDH does not seem to be 
a valuable diagnostic or even prognostic parameter in HCL patients.  
Despite the excellent initial response of HCL to PNA, at least 30-40% of the patients will relapse after 5 to 10 
years [4]. Until now, there is no early predictive parameter to identify patients at risk. Unlimited follow-up is 
needed in all patients including repeated bone marrow examinations with its known limits in regards to sampling 
error and limit of detection [27]. SIL2R is therefore a less invasive and well-established parameter to assess 
disease activity in peripheral blood samples [18]. This is especially true in patients treated with IFNα, because of 
its unlimited treatment time and the possibility to taper down the dose in relation to sIL2R values. However, 
absolute values are not directly linked to the amount of HCL cells and not comparable between patients. They 
are therefore of no use as predictive markers. For that reason, we built a ratio between the pretreatment value and 
the measurement after 1 and 3 months. A correlation between the ratio and achieving a CR was calculated, 
because almost all patients achieved a CR (91%). However, the ratio at 1 and 3 months treatment time is 
significantly associated to the time to CR. Therefore, sIL2R can be used as an early marker for response. 
Independent of the choice of first-line therapy (IFNα or CDA), in three quarter of cases a relative drop of the 
sIL2R ratio of at least 50% after 1 month of therapy start was observed. This led to CR within 3.9m (median, 
IQR 2.5-8.9m). Equal results could be seen after 3 months with a drop of at least 80%..Regarding our results, a 
relative decrease of the sIL2R ratio of at least 50% after one and/or a relative decrease of 80% after 3 months 
can be regarded as predictor for CR within the first 8 months of treatment. Therefore, a periodically assessment 
of sIL2R is advisable. 
In addition to the well-known sIl2R, we were looking for an association between IL28B genotype and treatment 
response in HCL patients on IFNα therapy. Because of the high effectivity of IFNα in almost all HCL patients, 
one could assume a direct link of the CC genotype and the disease itself. However, the genotype distribution in 
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our cohort was coherent with the current published literature [28, 29] in HCV patients and therefore excludes a 
direct link of the CC genotype and HCL. The second hypothesis of a faster, deeper or longer lasting response of 
the patients with a CC genotype treated with IFNα could not be proven. Explaining factors for our findings are 
the small sample size, confounding factors like treatment tolerance and follow-up time. The last point is of 
critical importance in all HCL studies, because of the excellent prognosis in these patients.  
IFNα showed significantly less early side effects in the only randomized trial comparing Pentostatin and IFNα 
and showed less early deaths [9]. The question of secondary malignancies, one of the main long-term side effects 
is still an open one in HCL patients and needs to be closely looked at. The largest study about this question from 
Hisada et al. found an increase in secondary malignancies analysing more than 3000 HCL patients. The increase 
was statistically significant in patients treated with chemotherapy and in the group diagnosed between 1990 and 
2002 including mainly patients treated with PNA [30]. Federico et al. included more than 1000 mainly IFNα 
treated patients and could not find such a difference in the estimated rate of secondary cancers [31]. Our study 
with a remarkable long median follow-up time of 14 years (median) showed a rate of 16% of patients with 
secondary malignancies, which is in line with the results of Federico et al. and others [22]. Due to the small 
sample size and the non-randomized study design, no additional conclusion in regards to late toxicity can be 
drawn. However, patients need to be informed about the risk for secondary malignancies and physicians should 
be vigilant for clinical signs of lymphoid, but as well solid cancers as found in our cohort and long follow-up 
times are essential to further investigate incidence of secondary cancers in HCL patients.  
 
The limitations of our study are the small patient number and the retrospective design. However, the influence of 
IL28B genotype on IFNα treatment concepts was only recently recognized and prospective analysis with 
sufficient follow-up time is not realistic. In addition, the size of the study population needs to be viewed in the 
context of the rarity of HCL and the special treatment concept. 
 
In conclusion, this study proofs that IFNα is still a valid treatment option in HCL, despite the fact that guidelines 
are reluctant to recommend it [6]. Whereas in the treatment of myeloproliferative neoplasm IFNα is increasingly 
used [32], the recognition in HCL is different. Tolerability remains one of the main argument against the use of 
IFNα [33], despite significantly less side effects and a lower mortality rate found in the only fully published, 
randomized study comparing IFNα and PNA [9]. Our study shows a good long-term tolerability with an 
excellent disease control. By using our sIL2R ratio, patients responding well to the treatment can be recognized 
early in the treatment. However, IL28B genotype has no influence on IFNα treatment response. 
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TABLES 
Table 1: Characteristics study cohort 
 
  
 
 
First line therapy 
Interferon-α 
 
 Yes No Overall 
Number of patients (percent) 24 (65) 13 (35) 37 (100) 
Age at diagnosis years - median (IQR) 46 (39-52) 45 (40-66) 45 (40-52) 
Sex - number (percent)    
  Male 19 (79) 10 (77) 29 (78) 
 Female 5 (21) 3 (23) 8 (22) 
Follow-up time years - median (IQR) 17 (12-28) 6 (2-13)  14 (7-23) 
Genotype - number (percent)    
 Genotype CC 10 (42) 5 (38) 15 (41) 
 Genotype CT/TT 12 (50) 7 (54)  19 (51) 
 Genotyping not successful 2 (8) 1 (8) 3 (8)  
Pretreatment splenectomy - number (percent) 14 (58) 4 (31) 18 (49) 
Complete remission achieved - number (percent) 20 (83) 11 (84) 31 (84) 
Relapse - number (percent) 5 (21) 6 (46) 11 (30) 
Resistance - number (percent) 1 (4) 0 1 (3) 
Hematological parameters - median (IQR)    
 Hemoglobin g/l   107 (73-122) 
 Neutrophil granulocytes G/l   0.5 (0.3-1.2) 
 Monocytes G/l   0.0 (0.0-0.3) 
 Platelets G/l   75 (46-129) 
Hairy cells in peripheral blood - number (percent)   27 (90) 
LDH U/l - median (IQR)   314 (267-359) 
sIL2R U/ml - median (IQR)   27'768 (16'984-540'000) 
Spleen size cm - median (IQR)   17 (13-21) 
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Table 2: Characteristics IFN-subgroup 
 Genotype 
 CC CT/TT 
Number of patients (percent) 10 (42) 12 (50) 
Age at diagnosis years - median (IQR) 46 (36-54) 45 (39-53) 
Sex - number (percent)   
 Male 9 (90) 9 (75) 
 Female 1 (10) 3 (25) 
Follow-up time years - median (IQR) 20 (11-33) 16 (14-26) 
Pretreatment splenectomy - number (percent) 7 (70) 6 (50) 
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Table 3: Follow-up IFN-subgroup 
 
Genotype Significance 
 CC CT/TT  
Number of patients (percent) 10 (45) 12 (55)  
Complete remission achieved - number (percent) 10 (100) 10 (83) 0.481 
Relapse - number (percent) 2 (20) 3 (25) 1.000 
Resistance - number (percent) 0 (0) 1 (8) 1.000 
Amount of complications under therapy  7  8 1.000 
Maintenance therapy - number of patients (percent) 5 (50) 6 (50) 1.000 
Discontinuation of therapy - number (percent) 5 (50) 6 (50) 1.000 
Second line therapy initiated - number (percent) 3 (30) 5 (42) 0.675 
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Table 4: Secondary malignancies 
Patient Second 
cancer 
Age at 
diagnosis of 
2° cancer 
(y) 
Therapies 
(1st line, 2nd 
line) 
3rd line 
therapy 
Time after 
diagnosis 
(y) 
Time 
after 
IFN (y) 
Time 
after 
PNA (y) 
1 Melanoma 
(T1) 
41 Splenectomy 
IFN 
- 5 5 - 
2 Mamma-Ca 52 IFN CDA 13 13 9 
3 Spinalioma 73 CDA CDA 7 - 4 
4 Basalioma 67 Splenectomy 
IFN 
- 6 3 - 
5 Prostate-Ca 
(T3) 
75 Splenectomy 
IFN 
Pentostatin 25 23 22 
6 Prostate-Ca 
(T1) 
75 IFN - 8 8 - 
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VISUAL ABSTRACT 
 
 
Negative	correlation	of	relative	decrease	in	sIL2-level	to	time	to	response		
	
	
	
	
	
	
	
	
	
	
%	decrease	of	sIL2-level	after	30	d	of	therapy	
%	decrease	of	sIL2-level	after	90	d	of	therapy	
linear	%	decrease	of	sIL2-level	after	30d/time	to	response	
linear	%	decrease	of	sIL2-level	after	90d/time	to	response	
x:	sIL-2	level	in	%	(100%	comply	with	level	before	therapy)	
y:	number	of	days	to	therapeutic	response		
